These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6487506)

  • 1. Study of the bioavailability of pindolol in malabsorption syndromes.
    Evard D; Aubry JP; Le Quintrec Y; Cheymol G; Cheymol A
    Br J Clin Pharmacol; 1984 Oct; 18(4):632-7. PubMed ID: 6487506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of pindolol absorption in malabsorption syndromes].
    Evard D; Le Quintrec Y; Aubry JP; Cheymol G; Cheymol A
    Gastroenterol Clin Biol; 1983 Apr; 7(4):398-404. PubMed ID: 6873552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a new beta-adrenoceptor blocking agent, LF 17-895, in man.
    Gugler R; Kreis L; Dengler HJ
    Arzneimittelforschung; 1975 Jul; 25(7):1067-72. PubMed ID: 241357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets.
    Aellig WH; Nüesch E; Pacha W
    Eur J Clin Pharmacol; 1982; 21(6):451-5. PubMed ID: 7075650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopharmacological studies with pindolol following intravenous and oral administration].
    Aellig WH
    Adv Clin Pharmacol; 1976; 11():9-13. PubMed ID: 1032575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pindolol availability in hypertensive patients with normal and impaired renal function.
    Chau NP; Weiss YA; Safar ME; Lavene DE; Georges DR; Milliez PL
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):505-10. PubMed ID: 913016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of mepindolol sulphate.
    Bonelli J; Hitzenberger G; Krause W; Wendt H; Speck U
    Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):169-76. PubMed ID: 6103882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the absolute oral bioavailability of pindolol by two analytical methods.
    Guerret M; Cheymol G; Aubry JP; Cheymol A; Lavene D; Kiechel JR
    Eur J Clin Pharmacol; 1983; 25(3):357-9. PubMed ID: 6628523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum protein-binding.
    Bergrem H; Opedal I
    Scand J Gastroenterol; 1983 May; 18(4):545-9. PubMed ID: 6669930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.
    Meier J; Nüesch E
    Br J Clin Pharmacol; 1977 Jun; 4(3):371-2. PubMed ID: 901706
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.
    Lavene D; Weiss YA; Safar ME; Loria Y; Agorus N; Georges D; Milliez PL
    J Clin Pharmacol; 1977; 17(8-9):501-8. PubMed ID: 893736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of kinetic methods to evaluate D-xylose malabsorption in patients.
    Breiter HC; Craig RM; Levee G; Atkinson AJ
    J Lab Clin Med; 1988 Nov; 112(5):533-43. PubMed ID: 3183487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal malabsorption and zidovudine bioavailability.
    Guarino A; Albano F; Castaldo A; Spagnuolo MI; Canani RB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 May; 18(1):91-2. PubMed ID: 9593465
    [No Abstract]   [Full Text] [Related]  

  • 14. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes.
    Lo CW; Paris PW; Clemens TL; Nolan J; Holick MF
    Am J Clin Nutr; 1985 Oct; 42(4):644-9. PubMed ID: 4050723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-pass effect of the beta-adrenoceptor blocking agent pindolol in the dog [proceedings].
    Meier J; Wagner O; Berde B
    Br J Pharmacol; 1977 Mar; 59(3):492P. PubMed ID: 843730
    [No Abstract]   [Full Text] [Related]  

  • 16. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bioavailability of two beta-blockers preadsorbed onto charcoal.
    Roivas L; Ojala-Karlsson P; Neuvonen PJ
    Methods Find Exp Clin Pharmacol; 1994 Mar; 16(2):125-32. PubMed ID: 7911863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes.
    Parsons RL
    Clin Pharmacokinet; 1977; 2(1):45-60. PubMed ID: 322910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of warfarin in a patient with severe short bowel syndrome.
    Kearns PJ; O'Reilly RA
    JPEN J Parenter Enteral Nutr; 1986; 10(1):100-1. PubMed ID: 3945042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.
    Aellig WH; Nüesch E; Engel G; Grevel J; Niederberger W; Rosenthaler J
    Br J Clin Pharmacol; 1986 Jan; 21(1):45-51. PubMed ID: 2868747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.